03 November 1997
Role of dopaminergic receptor agonists in the treatment of Parkinson's disease
Zygmunt Jamrozik, Piotr JanikMed Sci Monit 1997; 3(6): RA948-955 :: ID: 501846
Abstract
The efficiency of long time treatment by levodop of Parkinson's disease (PD) is limited to occurrence of side syndromes in the form of movement disorders such as: fluctuations, diskinesia, the decrease of effectiveness of the drug. The causes of their occurrence connected with loss of dopaminergic cells, pharmacodynamics, pharmacokinetic of levodop, changes in affinity of dopamine receptors (D), pathology of other structures outside the nigrostrial pathways. The discovery of the family of dopamine receptors D1, D2, D3, D4 and D5 and their differentiated effect on the functions of exrapyramidal system allowed the use of the strategy of more selective reaction on particular receptors. Dopamine receptor agonists (DAAG) have some positive characteristics from the clinical point of view and theoretical comparison to levodop. Those drugs are not metabolized to active chemicals, do not produce toxic metabolites or free radicals, their effectiveness in a smaller degree is depended on degree of damage of presynaptic elements. DAAG effectively brings back the balance in the neurotransmission of neuropeptides in striatum and decrease rotation of endogenic dopamine. Among actually available DAAG at least three have potential neuroprotective action. Former clinical xperiments show that use of this drugs is particularly desirable in two groups of patients. First consists of young patients, that had been not treated yet, particularly successible to fast occurrence of levodopic complications, in whom the use of DAAG in monotherapy allows to decrease the risk of far complications. The second group consists of patients treaded with levadop, with developed side symptoms, which cannot be satisfactorily control with the help of antycholinergic drugs, amontadine, benzodiazapine.
Keywords: basal ganglia, dopaminergic receptor agonists
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Comparing Neuromuscular Blockade Measurement Between Upper Arm (TOF Cuff®) and Eyelid (TOF Scan®) Using Miv...Med Sci Monit In Press; DOI: 10.12659/MSM.943630
11 Mar 2024 : Clinical Research
Enhancement of Frozen-Thawed Human Sperm Quality with Zinc as a Cryoprotective AdditiveMed Sci Monit In Press; DOI: 10.12659/MSM.942946
12 Mar 2024 : Database Analysis
Risk Factors of Age-Related Macular Degeneration in a Population-Based Study: Results from SHIP-TREND-1 (St...Med Sci Monit In Press; DOI: 10.12659/MSM.943140
12 Mar 2024 : Clinical Research
Preoperative Blood Transfusion Requirements for Hemorrhoidal Severe Anemia: A Retrospective Study of 128 Pa...Med Sci Monit In Press; DOI: 10.12659/MSM.943126
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952